## Matthias Lechmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11771797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The CD83 Molecule – An Important Immune Checkpoint. Frontiers in Immunology, 2020, 11, 721.	4.8	86
2	CD83 expression is essential for Treg cell differentiation and stability. JCI Insight, 2018, 3, .	5.0	42
3	FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival. Oncolmmunology, 2017, 6, e1256526.	4.6	44
4	Opposing functions of thymic stromal lymphopoietin–responsive basophils and dendritic cells in a mouse model of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 1443-1446.e8.	2.9	21
5	Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo. Immunobiology, 2015, 220, 270-279.	1.9	28
6	Topical Application of Soluble CD83 Induces IDO-Mediated Immune Modulation, Increases Foxp3+ T Cells, and Prolongs Allogeneic Corneal Graft Survival. Journal of Immunology, 2013, 191, 1965-1975.	0.8	60
7	Thymic Stromal Lymphopoetin-Induced Expression of the Endogenous Inhibitory Enzyme SLPI Mediates Recovery from Colonic Inflammation. Immunity, 2011, 35, 223-235.	14.3	97
8	Aptamer-Facilitated Biomarker Discovery (AptaBiD). Journal of the American Chemical Society, 2008, 130, 9137-9143.	13.7	181
9	The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations <i>in vivo</i> . Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11887-11892.	7.1	36
10	Herpes Simplex Virus Type 1 Induces CD83 Degradation in Mature Dendritic Cells with Immediate-Early Kinetics via the Cellular Proteasome. Journal of Virology, 2007, 81, 6326-6338.	3.4	73
11	Determination of the inhibitory activity and biological half-live of soluble CD83: Comparison of wild type and mutant isoforms. Immunobiology, 2006, 211, 449-453.	1.9	13
12	CD83 is a dimer: Comparative analysis of monomeric and dimeric isoforms. Biochemical and Biophysical Research Communications, 2005, 329, 132-139.	2.1	37
13	Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83. Journal of Experimental Medicine, 2004, 200, 345-351.	8.5	133
14	The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology, 2004, 209, 129-140.	1.9	43
15	Overexpression, Purification, and Biochemical Characterization of the Extracellular Human CD83 Domain and Generation of Monoclonal Antibodies. Protein Expression and Purification, 2002, 24, 445-452.	1.3	39
16	CD83 on dendritic cells: more than just a marker for maturation. Trends in Immunology, 2002, 23, 273-275.	6.8	214
17	Role of CD83 in the Immunomodulation of Dendritic Cells. International Archives of Allergy and Immunology, 2002, 129, 113-118.	2.1	92
18	The Extracellular Domain of CD83 Inhibits Dendritic Cell–mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells. Journal of Experimental Medicine, 2001, 194, 1813-1821.	8.5	168